In 2023, Mexico led in hospital discharges for hyperplasia of the prostate with 22.04 thousand discharges, followed by Canada with 13.35 thousand. Belgium showed a moderate number at 9.17 thousand, while Israel and Ireland reported lower figures at 3.89 thousand and 0.449 thousand, respectively.
Year-on-year variations in 2023 indicated growth in Mexico (0.58%) and Israel (0.96%), suggesting rising occurrences or better diagnosis. Conversely, Canada experienced a slight decline (-0.96%), and Ireland saw a substantial decrease (-6.16%), which could reflect improvements in preventive care or data discrepancies.
For future trends, watch for:
- Technological advancements in treatment reducing hospital stays.
- Increased awareness potentially leading to early diagnosis and discharges.
- Healthcare policy changes impacting discharge rates across countries.
Top countries in Hospital Discharges for Hyperplasia of Prostate by Country
| # | 5 Countries | Units (Hospital Discharges) | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Mexico | 22,040 | 2023 | +14.22% | +0.58% | View data |
| 2 | 2 Canada | 13,350 | 2023 | +3.76% | -0.96% | View data |
| 3 | 3 Belgium | 9,170 | 2023 | +3.78% | +0.041% | View data |
| 4 | 4 Israel | 3,890 | 2023 | -0.23% | +0.96% | View data |
| 5 | 5 Ireland | 449 | 2023 | -3.38% | -6.16% | View data |
